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Background: Little is known about the natural course of atherosclerotic plaque in the carotid artery
bifurcation. This study investigated the growth pattern of calciﬁcations in atherosclerotic carotid arteries
and its determinants using serial multi-detector CT angiography (MDCTA).
Methods: From a cohort of consecutive patients with TIA or ischemic stroke and a baseline MCDTA scan of
the carotid arteries, subjects were invited for a follow-up scan after 4e6 years. Calciﬁcation volumes
were scored semi-automatically on baseline and follow-up scans. Progression of calciﬁcation and its
determinants were analyzed in two ways: 1. as incidence of newly detectable calciﬁcation in patients free
of calciﬁcation at baseline, using logistic regression analysis; 2. as annual change in calciﬁcation volume
in all patients, using linear regression analysis.
Results: Two-hundred-twenty-two patients (aged 61.0  9.6 years, follow-up time 4.7  0.8 years) were
included. Calciﬁcation volumes increased signiﬁcantly (median 2.9 mm3 at baseline versus 9.4 mm3 at
follow-up, p < 0.001). Newly detectable calciﬁcation during follow-up was found in 27 out of 67 patients
without baseline calciﬁcation (40.3%) and was independently associated with age (OR 4.6 per 10 years
increase in age, p < 0.001) and hypertension (OR 8.2, p ¼ 0.008). Annual calciﬁcation growth was
independently associated with age, calciﬁcation load, glucose, hypertension, and smoking. Baseline
calciﬁcation load was the most important risk factor for calciﬁcation growth in multivariable analysis.
Conclusion: Several modiﬁable cardiovascular risk factors are associated with carotid calciﬁcation growth,
however, time and baseline calciﬁcation load remain the most important determinants of calciﬁcation
development.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
Carotid artery atherosclerosis is one of the major causes of
ischemic stroke. Atherosclerotic plaque may rupture, leading to
thrombus formation and embolization of atherosclerotic debris or
thrombus material into distally located arteries.
Carotid calciﬁcation has been used as a surrogate marker for
carotid atherosclerosis in studies on stroke risk prediction [1e3].
Little data is published on the determinants of carotid calciﬁcation.
A few cross-sectional studies on asymptomatic subjects demon-
strated the relation between classical cardiovascular risk factors
and the presence or volume of calciﬁcation [4e6]. However, espe-
cially in symptomatic patients, who have a high risk of recurrentax: þ31 (0)10 7034033.
.J. van Gils), mathijsb87@
(L.G.M. Cremers), d.dippel@
c.nl (A. van der Lugt).
 the Elsevier OA license. events, it might be of clinical importance to predict and inﬂuence
further plaque development. Although currently available non-
invasive imaging techniques enable the monitoring of carotid
calciﬁcation growth in vivo, calciﬁcation development in the
carotid arteries has never been studied longitudinally.
In this study, we therefore investigated the growth pattern of
calciﬁcations in atherosclerotic carotid arteries and its determi-
nants using serial multi-detector CT angiography (MDCTA) imaging
in patients with recent ischemic stroke or TIA.
2. Methods
2.1. Study population
Patients were recruited from a prospective registry of patients
with amaurosis fugax, transient ischemic attack or minor ischemic
stroke (Rankin score < 4) who underwent an MDCTA of the carotid
arteries as part of their clinical work-up [7]. Follow-up scans were
performed after 4e6 years in a subgroup. Inclusion criterion for this
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both carotid arteries, deﬁned as thickening and/or calciﬁcation of
the vessel wall. Exclusion criteria were: bilateral occlusion and/or
invasive treatment of the carotid artery, no informed consent, renal
insufﬁciency, hyperthyroidism and poor image quality of the
baseline scan. The ﬂow chart in Fig. 1 shows the selection process of
patients for this serial study. Clinical measures and information on
risk factors and medication use were obtained from ﬁrst admission
to the hospital and information on recurrent ischemic cerebro-
vascular events and medication use was obtained at the time of the
follow-up scan. This study was approved by the Institutional Ethics
Review Board.
2.2. Scan protocol
Baseline scans were performed on a 16- or 64-slice MDCT
scanner (Siemens, Sensation16/64, Erlangen, Germany) with
a standardized optimized contrast-enhanced protocol (collimation
16 0.75mm or 2 32 0.6 mm, pitch 1, 120 kV). The scan ranged
from the ascending aorta to the intracranial circulation. The follow-
up scans were performed on a 128-slice MDCT scanner (Siemens,
Flash, Erlangen, Germany) with a comparable protocol (collimation
2 64 0.6 mm, pitch 0.7, 120 kV) and a scan range of 6 cm around
the bifurcation. To test for differences in in-plane resolution
between similar kernels on different scanners, we performed
a point-spread-function analysis using a standard thin wire
phantom [8]. No differences were found. 80 mL of contrast material
was used, with a 40 mL saline bolus chaser and real time bolus
tracking in the ascending aorta, using a threshold of 120 HU.
Image reconstructions were made with an FOV of 120 mm,
matrix size of 512  512 mm, a slice thickness of 1.0 mm, an
increment of 0.6 and a smooth (B30) as well as an intermediate
(B46) reconstruction algorithm.
2.3. Analysis of calciﬁcation
Calciﬁcation measurements were done with a commercially
available software package on a standaloneworkstation (Leonardo-
Siemens Medical Solutions, Forchheim, Germany). To determine
the presence and quantity of carotid calciﬁcation, one observer
blinded to the clinical history evaluated the axial images of the
MDCT data sets. Calciﬁcationwas semi-automatically scoredwithin
a range of 3 cm above to 3 cm under the carotid bifurcation orFig. 1. Flow chart depicting patient sea range as long as possible given the scan range at follow-up. The
analyzed range on baseline and follow-up was ﬁxed within one
patient. A threshold of 600 HU was chosen to enable an automatic
differentiation between contrast medium in the lumen and calci-
ﬁcations in the vessel wall [9]. Volume scoring results in low rescan
variability [10] and a volume score using a threshold of 600 HU has
a high intra- and inter-observer repeatability [9]. As a default, an
intermediate convolution kernel (B46) was used for reconstruction
of the baseline and follow-up MDCTA [11]. In case no B46 kernel
was available either at baseline or follow-up, the smooth B30 kernel
was used to compare calciﬁcation volumes on both MDCTA scans.
Intra-observer and inter-observer reproducibility of this method
were deﬁned in a subset of 40 consecutive data sets and were very
good (intra-class correlation coefﬁcients of 1.0 and coefﬁcients of
variation <3%).
2.4. Cardiovascular risk factors
Diabetes was deﬁned as fasting serum glucose levels over
7.9 mmol/l, nonfasting serum glucose levels over 11.0 mmol/l, or
use of anti-diabetic medication. Hypertension was deﬁned as
a mean systolic blood pressure over 140 mmHg and/or a mean
diastolic blood pressure over 90mmHg during 2 episodes of at least
15min of continuous non-invasive blood pressuremeasurement, or
on treatment with anti-hypertensive medication. Hypercholester-
olemia was deﬁned as fasting cholesterol over 5.0 mmol/l or on
treatment with cholesterol lowering drugs. Subjects were catego-
rized as current smoking versus non- and ever smoking. Besides
these dichotomized risk factor deﬁnitions, the continuous risk
factors glucose (in mmol/l), systolic blood pressure and diastolic
blood pressure (SBP and DBP, per 10 mmHg), and cholesterol level
(in mmol/l) at baseline were used as determinants in the analyses.
Information on medication use was obtained at baseline and at
follow-up. Information on a history of coronary artery disease
(deﬁned as a history of myocardial infarction, angina pectoris or
coronary artery bypass grafting) and on a history of ischemic
cerebrovascular disease (deﬁned as a clinical diagnosis of ischemic
stroke or transient ischemic attack) was collected.
2.5. Statistical analysis
Data are presented as mean SD, median interquartile ranges
(IQR) and percentages where appropriate. Differences betweenlection for this follow-up study.
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Whitney U test where appropriate.
The Wilcoxon-signed rank test was performed to test for
differences in baseline calciﬁcation volume and growth rate
between calciﬁcations in the left and right carotid arteries within
patients. No signiﬁcant differences in baseline calciﬁcation volume
(median 0.4 (IQR 0.0e13.6) versus 1.2 mm3 (IQR 0.0e14.2),
p ¼ 0.89) or in calciﬁcation growth (median 0.4 (IQR 0.0e3.0)
versus 0.6 mm3/year (IQR 0.0e3.5), p ¼ 0.62) between the left
and right carotid arteries were found. We therefore averaged
calciﬁcation volumes across both carotid arteries within a patient.
The calciﬁcation volumes of one side were taken in patients
treated unilaterally with carotid endarterectomy or stent place-
ment (n ¼ 21) or in patients with unilateral focal image artefacts
(n ¼ 1).
Because calciﬁcation volumes had a highly positively skewed
distribution, we used the natural log transformed values and added
1 mm3 to deal with patients who had an initial calciﬁcation volume
of zero [12]. The associations between the classical cardiovascular
risk factors and baseline calciﬁcation volumes (ln (calciﬁcation
volume þ 1)) were studied using linear regression analysis.
The changes in the amount of carotid calciﬁcationwere assessed
by subtracting the calciﬁcation volumes at baseline from those at
follow-up. To test for absolute progression in calciﬁcation volume
from baseline in the whole group, aWilcoxon-Signed Rank test was
used. The annualized calciﬁcation growth rate was calculated by
dividing the change in calciﬁcation volume by the actual number of
months that passed between the two scans, multiplied by 12. Two
endpoints of progression of calciﬁcation were analyzed separately
and were deﬁned as: 1. Incidence of detectable calciﬁcation in
patients free of detectable calciﬁcation at baseline and 2. Annual-
ized change in calciﬁcation volume in all patients. Associations
between risk factors and incidence of newly detectable calciﬁcation
at follow-up were assessed with logistic regression analysis in
a model adjusted for gender, age and scan interval (model I) and in
a multivariable model (II) including all variables from model I with
a p-value 0.05 and the strongest variable from two risk factors
deﬁnitions. Linear regression analysis was used to study determi-
nants of absolute annual calciﬁcation growth (ln (calciﬁcation
growth þ1)). Age, gender and variables with a p-value 0.05 (and
the strongest one from two risk factor deﬁnitions) from the age and
gender adjusted model (model I) were ﬁtted into the multivariable
regression model (model II).
To avoid an induced (spurious) correlation between change in
calciﬁcation and its baseline value, themean of calciﬁcation volume
at baseline and follow-up was used as the determinant “calciﬁca-
tion load” for the regression analyses [13].Table 1
Baseline patient characteristics.
All patients (n ¼ 222)
Age (years, mean  SD) 61.0  9.6
Diabetes mellitus 26 (11.7%)
Hypertension 152 (68.5%)
Hypercholesterolemia 175 (78.8%)
Smoking (current) 90 (40.5%)
History of CAD 30 (13.5%)
History of CVD 43 (19.4%)
Scan interval (years, mean  SD) 4.7  0.8
BL Ca volume (mm3, median, IQR) 2.9 (0.0e19.7)
FU Ca volume (mm3, median, IQR) 9.4 (0.7e41.9)
Annual Ca growth (mm3, median, IQR) 1.1 (0.1e4.2)
Values are means  standard deviation or median with interquartile range for continuou
artery disease, CVD ¼ cerebrovascular disease, BL ¼ baseline, FU ¼ follow-up, Ca ¼ calci
a Signiﬁcant difference between men and women at the level p  0.05, analyzed usin
b Signiﬁcant difference between men and women at the level of p ¼ 0.001, analyzed uStatistical signiﬁcance was assumed at a p-value of less than
0.05. All analyses were performed using SPSS version 20.0 for
Windows.
3. Results
Of the 527 potential candidates, 224 patients were included in
this study. The participating patients had a signiﬁcantly lower
prevalence of hypertension (68.8% versus 78.5%, p < 0.05) and
diabetes mellitus (11.6% versus 22.8%, p < 0.001), but were more
often smokers (40.6% versus 31.7%, p < 0.05) as compared to the
non-participating patients. In two cases, poor image quality due to
streak artefacts hampered an accurate calciﬁcation scoring of both
carotid arteries and these patients were therefore excluded.
The clinical indication for the baseline MDCTA of the included
patients was amaurosis fugax in 27 patients (12.2%), transient
ischemic attack in 92 patients (41.4%) and ischemic stroke in 103
patients (46.4%). Mean age of the patients at inclusion was
61.0  9.6 years and 64% of participants were male. No signiﬁcant
differences were found between men and woman in calciﬁcation
volumes at baseline and follow-up, or in annual calciﬁcation
growth. Average time between the two scans was 4.7  0.8 years
(Table 1). The majority of patients used from baseline or earlier:
cholesterol lowering drugs (92.8%), anti-hypertensive medication
(69.4%), anti-diabetic therapy (11.3%) and anti-platelets or anti-
coagulation (99%) (at follow-up 84.7%, 73.4%, 16.2% and 96%,
respectively).
Table I (online only) displays the associations between risk
factors and baseline calciﬁcation volume. Gender, age, diabetes
mellitus, glucose, and current smoking were signiﬁcant predictors
in model I and all variables put into model II remained signiﬁcantly
associated with baseline calciﬁcation volume in model II.
The calciﬁcation volumes in the whole group were signiﬁcantly
higher at follow-up (median 9.4 mm3, IQR 0.7e41.9) than at base-
line (median 2.9 mm3, IQR 0.0e19.7; Z ¼ 11.5, p < 0.001). Median
annual growth rate was 1.1 mm3 (IQR 0.1e4.2 mm3).
Sixty-seven patients had no detectable calciﬁcation at baseline.
Twenty-seven of these patients had newly detectable calciﬁcations
at follow-up (after 4.7 0.8 years), a cumulative incidence of 40.3%.
Median annual growth was 0.16 mm3 (IQR 0.06e0.66). Table 2
displays the associations between the presence of newly detect-
able calciﬁcation at follow-up and cardiovascular risk factors. Age,
scan interval, and hypertension were signiﬁcantly associated with
the occurrence of newly detectable calciﬁcation in model I. In
model II, the same determinants remained signiﬁcantly associated.
Patients with detectable calciﬁcation at baseline (n ¼ 155)
showed a median annual growth rate of 2.2 mm3 (IQR 0.8e6.4).Men (n ¼ 141, 63.5%) Women (n ¼ 81, 36.5%)
60.9  9.1 61.0  10.3
21 (14.9%) 5 (6.2%)
98 (69.5%) 54 (66.7%)
105 (74.5%) 70 (86.4%)a
54 (38.3%) 36 (44.4%)
25 (17.7%) 5 (6.2%)a
36 (25.5%) 7 (8.6%)a
4.8  0.9 4.4  0.7b
3.7 (0.0e25.9) 0.8 (0.0e13.6)
11.5 (1.1e58.5) 6.5 (0.2e32.3)
1.2 (0.1e5.5) 0.8 (0.0e3.4)
s variables and numbers (percentages) for dichotomous variables. CAD ¼ coronary
ﬁcation.
g a c2-test.
sing a t-test.
Table 2
Cardiovascular risk factors and newly detectable calciﬁcation at follow-up among
patients free of calciﬁcation at baseline (n ¼ 67).
OR (95%-CI)I OR (95%-CI)II
Male gender 0.43 (0.12e1.54) 0.34 (0.08e1.43)
Age(per 10 years) 4.01 (1.90e8.42)* 4.61 (1.85e11.49)*
Scan interval (per year) 3.16 (1.20e8.35)* 3.06 (1.04e9.02)*
Diabetes mellitus 0.97 (0.11e8.71)
Hypertension 7.95 (1.69e37.29)* 8.15 (1.73e38.34)*
Hypercholesterolemia 0.50 (0.12e2.05)
Smoking (current) 2.15 (0.49e9.41)
Glucose (mmol/l) 1.37 (0.74e2.52)
SBP (per 10 mmHg) 1.24 (0.93e1.67)
DBP (per 10 mmHg) 1.25 (0.75e2.11)
Cholesterol (mmol/l) 0.74 (0.43e1.28)
Values represent odds ratios (newly detected calciﬁcation versus no calciﬁcation at
follow-up) with 95% conﬁdence intervals (CI).
Model I: Adjusted for gender, age and scan interval.
Model II: Additionally adjusted for all signiﬁcant risk factors from model I with
a p-value 0.05.
*p < 0.05.
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did not show any progression at all and the other 150 patients all
showed some progression (min 0.03, max 37.4 mm3 per year).
The results of the linear regression analyses for calciﬁcation
growth in all patients (n ¼ 222) are displayed in Table II (online
only). Age, calciﬁcation load, diabetes mellitus, glucose, hyperten-
sion, and current smoking were signiﬁcant predictors for calciﬁ-
cation growth in model I. In model II, these same risk factors
remained signiﬁcantly associated.
Age and gender accounted for only 12% of the variability in
calciﬁcation growth. R2 signiﬁcantly increased by adding the risk
factors glucose, hypertension and smoking (R2 ¼ 0.22) or by adding
calciﬁcation load (R2 ¼ 0.44). R2 of the ﬁnal model II was 0.48.
Calciﬁcation load was therewith the most important determinant.
Its inﬂuence is also depicted in Fig. 2.
During follow-up, 37 patients experienced one or more recur-
rent ischemic events from the territories of the carotid arteries. No
differences in calciﬁcation volume at baseline or in calciﬁcation
growth were found between the patients with and those without
recurrent disease.Fig. 2. Graph shows the mean annual calciﬁcation growth in accordance with baseline
calciﬁcation volume categories. The different bars-and-whiskers represent: subjects
without calciﬁcation at baseline (n ¼ 67); subjects with calciﬁcation present at base-
line were divided into quartiles: ﬁrst quartile (n ¼ 39); second quartile (n ¼ 39); third
quartile (n ¼ 38) and fourth quartile (n ¼ 39).4. Discussion
4.1. Summary
In this serial MDCTA study, we investigated the in vivo growth
pattern of calciﬁcation and its determinants in atherosclerotic
carotid arteries of symptomatic patients. Calciﬁcation volume
signiﬁcantly increased compared to the baseline volume. We found
the cardiovascular risk factors age, serum glucose level, hyperten-
sion, and smoking to be associated with a fast annual calciﬁcation
growth. Furthermore, calciﬁcation load was the most important
predictor for absolute calciﬁcation growth. The development of
newly detectable calciﬁcation was associated with age and
hypertension.
4.2. Literature context
Large cross-sectional studies in carotid arteries have shown
that classical cardiovascular risk factors are associated with the
presence and amount of carotid calciﬁcation [4e6]. We found
similar risk factors associated with calciﬁcation volume and
calciﬁcation growth. No prospective studies investigating calciﬁ-
cation growth in the carotid arteries are available for comparison.
In contrast to calciﬁcation measures in the carotid arteries, coro-
nary artery calcium score (CAC) has already proven to be a marker
of risk of cardiovascular events and to have incremental prognostic
value beyond traditional risk factors [14]. Several large prospective
serial coronary calciﬁcation studies have been performed [15e21].
Our longitudinal study shows comparable ﬁndings with those
from prospective coronary artery studies. First, in prospective
coronary studies, comparable incidence rates, varying from 5 to
12% per year, were found [16e18,22]. In agreement with those
studies [17,18] we found age and hypertension as risk factors for
incidence of detectable calciﬁcation. Secondly, in this study calci-
ﬁcation load was the dominant predictor of fast calciﬁcation
growth. Baseline calciﬁcation load was found to be the only
independent risk factor for calciﬁcation growth in some coronary
studies [20], and its importance was conﬁrmed in several others
[18,20e23]. This ﬁnding can be explained by the fact that the
chronic inﬂuence of risk factors is already reﬂected in the baseline
calciﬁcation volume, since baseline calcium itself is a part of the
pathophysiological process under investigation. When treated as
a determinant and corrected for in a multivariable model, the
effects of the other risk factors will diminish. Furthermore, in
a large community-based cohort (n ¼ 2807) of subjects having
coronary calciﬁcation at baseline, body mass index, a family
history of heart attack, diabetes mellitus, and glucose remained
signiﬁcantly associated with coronary calciﬁcation progression
after adjustment for baseline calciﬁcation burden [18]. Another
study found hypertension and diabetes mellitus to remain signif-
icant beside baseline calciﬁcation [21]. In addition to hypertension
and diabetes, we also found age and smoking to be related to fast
annual calciﬁcation growth.
This study ﬁlls a gap in the literature, since no prospective data
on calciﬁcation of carotid atherosclerotic plaques is available.
However, in carotid arteries, the clinical signiﬁcance of calciﬁcation
of plaques is not as clear as in the coronary arteries. Whereas some
studies suggest that degree of carotid calciﬁcation is associated
with increased stroke risk [1,3,24], others found that a relatively
high calciﬁcation content of carotid plaques is associated with
plaque stabilization [25e29]. The relative proportion of calciﬁca-
tion within plaques seems to be of signiﬁcant importance. Future
work should therefore focus on the determinants of relative calci-
ﬁcation contribution within carotid plaques and on the relation
between (relative) calciﬁcation burden and recurrent stroke.
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Advantages of this study are its longitudinal and in vivo nature,
which increases the sensitivity for ﬁnding predictors of carotid
calciﬁcation progression.
Whereas most longitudinal studies are performed on asymp-
tomatic subjects, a symptomatic stroke population was the subject
of this study. Once having experienced an ischemic cerebrovascular
event, patients are prone to recurrent events. It is therefore
important to perform longitudinal atherosclerotic studies on
symptomatic patients. However, methodological obstacles are
introduced, since most patients already use one or several drugs for
secondary prevention. We have to be aware of an obvious mingling
of possible inﬂuences on plaque calciﬁcation growth: the ominous
effect of the risk factors and in addition the, possibly reverse,
inﬂuence of the drugs. For example in hypercholesterolemic
patients, statin use may reduce the progression of calciﬁcation [15].
In our prospective, observational study it is impossible to unravel
these different inﬂuences. To completely separate possible drug
effects from risk factor inﬂuences, a randomized clinical trial should
be performed.
Furthermore, in contrast to the 130 HU threshold used in non-
contrast enhanced scans, we used a threshold of 600 HU to be
able to automatically separate calciﬁcations from the dens contrast
material in the lumen. It can be questioned whether changes in
calciﬁcation burden are optimally caught by using this 600 HU
threshold. Both an increasing density of calciﬁcations as well as
circumferential expanding of the calciﬁcation dots might be partly
underscored, therewith underestimating calciﬁcation growth and
its variability. This may reduce the sensitivity for ﬁnding signiﬁcant
associations with determinants. However, the same would hold for
the standard quantiﬁcation methods using a threshold of 130 HU.
Moreover, Glodny et al. found a strong, linear correlation between
the calciﬁcation volumes derived using a threshold of 600 HU on
coronary CT angiographies and the calciﬁcation volumes derived
using 130 HU as a threshold or the Agatston score on non-contrast
enhanced scans [9].
5. Conclusion
In this study, we presented the determinants of calciﬁcation
growth in the carotid arteries, ﬁlling a gap in the literature.
Although several modiﬁable classical cardiovascular risk factors are
associated, age and especially calciﬁcation load are the most
important predictors for calciﬁcation progression. These ﬁndings
should be taken into account in the design of future studies that
investigate the determinants of calciﬁcation proportion within
carotid plaques and the relation between calciﬁcation changes and
recurrent ischemic cerebrovascular events.
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